AR057911A1 - Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento - Google Patents
Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamentoInfo
- Publication number
- AR057911A1 AR057911A1 ARP060105065A ARP060105065A AR057911A1 AR 057911 A1 AR057911 A1 AR 057911A1 AR P060105065 A ARP060105065 A AR P060105065A AR P060105065 A ARP060105065 A AR P060105065A AR 057911 A1 AR057911 A1 AR 057911A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- halo
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 16
- -1 Pyrimidinyl benzothiophene compound Chemical class 0.000 abstract 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010023774 Large cell lung cancer Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000009546 lung large cell carcinoma Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73809705P | 2005-11-18 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057911A1 true AR057911A1 (es) | 2007-12-26 |
Family
ID=38345605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105065A AR057911A1 (es) | 2005-11-18 | 2006-11-17 | Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7547691B2 (enExample) |
| EP (1) | EP1989200B1 (enExample) |
| JP (1) | JP2009516697A (enExample) |
| KR (1) | KR100990771B1 (enExample) |
| CN (1) | CN101309918B (enExample) |
| AR (1) | AR057911A1 (enExample) |
| AT (1) | ATE437873T1 (enExample) |
| AU (1) | AU2006337626B2 (enExample) |
| BR (1) | BRPI0618245A2 (enExample) |
| CA (1) | CA2629336A1 (enExample) |
| CR (1) | CR9947A (enExample) |
| DE (1) | DE602006008187D1 (enExample) |
| DK (1) | DK1989200T3 (enExample) |
| EA (1) | EA014426B1 (enExample) |
| EC (1) | ECSP088456A (enExample) |
| ES (1) | ES2329085T3 (enExample) |
| IL (1) | IL190489A0 (enExample) |
| MA (1) | MA30053B1 (enExample) |
| NO (1) | NO20082594L (enExample) |
| PE (1) | PE20070833A1 (enExample) |
| PL (1) | PL1989200T3 (enExample) |
| PT (1) | PT1989200E (enExample) |
| SI (1) | SI1989200T1 (enExample) |
| TN (1) | TNSN08227A1 (enExample) |
| TW (1) | TW200800201A (enExample) |
| WO (1) | WO2007092095A2 (enExample) |
| ZA (1) | ZA200803940B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| US8101628B2 (en) | 2006-12-21 | 2012-01-24 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| SI2125794T1 (sl) * | 2006-12-21 | 2011-02-28 | Lilly Co Eli | Spojine imidazolidinonil aminopirimidina za zdravljenje raka |
| WO2008144222A2 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| EA016781B1 (ru) | 2007-05-16 | 2012-07-30 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| EP2924023A1 (en) | 2008-06-30 | 2015-09-30 | Janssen Pharmaceutica NV | piperidine und piperazine derivativs |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| KR101123178B1 (ko) * | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| KR20120059558A (ko) | 2009-08-19 | 2012-06-08 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 화합물 및 이의 사용 방법 |
| JP5634596B2 (ja) | 2010-04-27 | 2014-12-03 | ハチソン メディファーマ リミテッド | ピリミジニルインドール化合物 |
| US20140194383A1 (en) | 2011-04-07 | 2014-07-10 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
| US9245773B2 (en) | 2011-09-02 | 2016-01-26 | Taiwan Semiconductor Manufacturing Company, Ltd. | Semiconductor device packaging methods and structures thereof |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| AU2013216935C1 (en) | 2012-02-08 | 2017-12-14 | John Emmerson Campbell | Heteroaryl compounds and methods of use thereof |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| CN105085434B (zh) * | 2014-05-09 | 2018-02-09 | 上海特化医药科技有限公司 | 硫乙拉嗪或其中间体的制备方法 |
| US9796699B2 (en) | 2015-11-03 | 2017-10-24 | Janssen Pharmaceutica Nv | Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| SG10202100724UA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
| US20260116871A1 (en) * | 2024-10-24 | 2026-04-30 | Fujian Haixi Pharmaceuticals Co., Ltd. | Tyrosine Kinase Inhibitors and Uses Thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| AU2005316312B2 (en) | 2004-12-17 | 2009-10-22 | Amgen, Inc. | Aminopyrimidine compounds and methods of use |
-
2006
- 2006-10-23 TW TW095139053A patent/TW200800201A/zh unknown
- 2006-11-15 PT PT06850430T patent/PT1989200E/pt unknown
- 2006-11-15 ES ES06850430T patent/ES2329085T3/es active Active
- 2006-11-15 CN CN2006800428126A patent/CN101309918B/zh not_active Expired - Fee Related
- 2006-11-15 EA EA200801362A patent/EA014426B1/ru not_active IP Right Cessation
- 2006-11-15 EP EP06850430A patent/EP1989200B1/en active Active
- 2006-11-15 US US12/093,024 patent/US7547691B2/en not_active Expired - Fee Related
- 2006-11-15 DE DE602006008187T patent/DE602006008187D1/de active Active
- 2006-11-15 SI SI200630446T patent/SI1989200T1/sl unknown
- 2006-11-15 DK DK06850430T patent/DK1989200T3/da active
- 2006-11-15 CA CA002629336A patent/CA2629336A1/en not_active Abandoned
- 2006-11-15 JP JP2008541463A patent/JP2009516697A/ja not_active Ceased
- 2006-11-15 AT AT06850430T patent/ATE437873T1/de active
- 2006-11-15 WO PCT/US2006/060911 patent/WO2007092095A2/en not_active Ceased
- 2006-11-15 AU AU2006337626A patent/AU2006337626B2/en not_active Ceased
- 2006-11-15 BR BRPI0618245-3A patent/BRPI0618245A2/pt not_active IP Right Cessation
- 2006-11-15 PL PL06850430T patent/PL1989200T3/pl unknown
- 2006-11-15 KR KR1020087011830A patent/KR100990771B1/ko not_active Expired - Fee Related
- 2006-11-15 PE PE2006001456A patent/PE20070833A1/es not_active Application Discontinuation
- 2006-11-17 AR ARP060105065A patent/AR057911A1/es unknown
-
2008
- 2008-03-27 IL IL190489A patent/IL190489A0/en unknown
- 2008-04-29 CR CR9947A patent/CR9947A/es not_active Application Discontinuation
- 2008-05-08 ZA ZA200803940A patent/ZA200803940B/xx unknown
- 2008-05-16 TN TNP2008000227A patent/TNSN08227A1/en unknown
- 2008-05-16 EC EC2008008456A patent/ECSP088456A/es unknown
- 2008-06-10 NO NO20082594A patent/NO20082594L/no not_active Application Discontinuation
- 2008-06-13 MA MA31035A patent/MA30053B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009516697A5 (enExample) | ||
| AR070460A1 (es) | Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| EA200970656A1 (ru) | Вич-ингибирующие 5,6-замещенные пиримидины | |
| WO2003057688A3 (en) | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators | |
| AR057209A1 (es) | Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| WO2008007123A3 (en) | Pharmaceutical compounds | |
| AR097862A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR049894A1 (es) | Derivados de prolina y sus usos como inhibodores de la enzima dipeptidilpeptidasa-iv | |
| BRPI0607756A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos | |
| PE20091414A1 (es) | FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR076928A1 (es) | Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| BRPI0717767A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| EA200701114A1 (ru) | Азоловые производные с антимускариновой активностью | |
| PE20090596A1 (es) | Imidazoles biciclicos fusionados | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| TW200628154A (en) | Organic compounds | |
| ECSP099441A (es) | Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |